Page last updated: 2024-11-13

butobendin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

butobendin: RN refers to (S-(R*,R*))-isomer; Craviten is tradename; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID74933456
MeSH IDM0096933

Synonyms (1)

Synonym
butobendin

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Comparison of the decline of the same absolute and relative serum concentrations of the drug and the variation of pharmacokinetic parameters with the dose leads to the conclusion, that the elimination of Craviten in rats cannot be described by first-order kinetics."( Pharmacokinetic investigations of Craviten. II. Dose-dependent elimination kinetics in rats following rapid intravenous injection.
Danek, A; Witek, J,
)
0.13

Bioavailability

ExcerptReferenceRelevance
" To increase bioavailability in men the tablets or enteric coated tablets should be made according to the results of clinical trials."( In vitro study of (2S, 2'S) N,N'-dimethyl-N, N'-bis [1(3', 4', 5'-trimethoxybenzoyloxy) butyl-2] ethylenediamine salts and their bioavailability.
Bartkowicz, S; Kluczykowska, B; Krówczyński, L; Stozek, T; Wajdowicz, A,
)
0.13

Dosage Studied

ExcerptRelevanceReference
"The aim of this study was to improve the oral dosage form of the title compound."( In vitro study of (2S, 2'S) N,N'-dimethyl-N, N'-bis [1(3', 4', 5'-trimethoxybenzoyloxy) butyl-2] ethylenediamine salts and their bioavailability.
Bartkowicz, S; Kluczykowska, B; Krówczyński, L; Stozek, T; Wajdowicz, A,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (7.14%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (3.57%)4.05%
Observational0 (0.00%)0.25%
Other25 (89.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]